Patient characteristics
| Characteristic . | No. . |
|---|---|
| No. of patients | 37 |
| Age, median (range) | 57 (22-66) |
| Male sex (%) | 20 (54) |
| AML (%) | 17 (46) |
| FAB subtype M0/M1/M2/M4/M5 | 2/5/7/1/2 |
| MDS (%) | 20 (54) |
| Hypoplastic/RAEB | 7/3 |
| RAEB-t | 7 |
| CMML | 3 |
| IPSS score20 | |
| Intermediate-1 | 7 |
| Intermediate-2 | 9 |
| High | 4 |
| Intensive treatment for MDS prior to transplantation (%) | 7 (35) |
| Time from diagnosis to transplantation, median mo (range) | 5 (1-55) |
| High-risk features at transplantation (%) | |
| Poor-risk cytogenetics* | 7 (19) |
| Secondary AML/MDS† | 1 (6)/5 (25) |
| Prior autologous transplantation | 4 (11) |
| Blasts in BM ≥ 10% at transplantation | 7 (19) |
| Nonearly disease phase at transplantation | 22 (59) |
| ECOG performance status ≥ 2 (%) | 3 (8) |
| Donor or recipient CMV seropositive (%) | 36 (97) |
| Sex mismatch‡ (%) | 14 (38) |
| CD34+ cells infused (× 106/kg recipient weight), median (range) | 5 (2-15) |
| Characteristic . | No. . |
|---|---|
| No. of patients | 37 |
| Age, median (range) | 57 (22-66) |
| Male sex (%) | 20 (54) |
| AML (%) | 17 (46) |
| FAB subtype M0/M1/M2/M4/M5 | 2/5/7/1/2 |
| MDS (%) | 20 (54) |
| Hypoplastic/RAEB | 7/3 |
| RAEB-t | 7 |
| CMML | 3 |
| IPSS score20 | |
| Intermediate-1 | 7 |
| Intermediate-2 | 9 |
| High | 4 |
| Intensive treatment for MDS prior to transplantation (%) | 7 (35) |
| Time from diagnosis to transplantation, median mo (range) | 5 (1-55) |
| High-risk features at transplantation (%) | |
| Poor-risk cytogenetics* | 7 (19) |
| Secondary AML/MDS† | 1 (6)/5 (25) |
| Prior autologous transplantation | 4 (11) |
| Blasts in BM ≥ 10% at transplantation | 7 (19) |
| Nonearly disease phase at transplantation | 22 (59) |
| ECOG performance status ≥ 2 (%) | 3 (8) |
| Donor or recipient CMV seropositive (%) | 36 (97) |
| Sex mismatch‡ (%) | 14 (38) |
| CD34+ cells infused (× 106/kg recipient weight), median (range) | 5 (2-15) |
FAB indicates French-American-British classification; RAEB, refractory anemia with excess blasts; RAEB-t, refractory anemia with excess blasts in transformation; CMML, chronic myelomonocytic leukemia; IPSS, International prognostic scoring system; ECOG, European Cooperative Oncology Group.
Includes cases with complex karyotypes, monosomy 7 and del(5); 9 patients had a normal karyotype and 19 had a cytogenetic abnormality not categorized as poor prognosis.
Includes 3 cases of secondary postautologous transplantation MDS, 2 cases of MDS secondary to chemotherapy and 1 case of AML secondary to chemotherapy.
Includes 8 cases (21%) of female donor to male recipient.